The tetrasaccharide 3-deoxy-a-D-manno-2-octulosonic acid (ac-KDO)(2--8)-ce-KDO(2->4)-ce-KDO(2-->6)-IGIcNAc, a partial structure of chlamydial lipopolysaccharide (LPS) representing a genus-specific epitope, was synthesized and covalently linked to bovine serum albumin, resulting in an artificial glycoconjugate antigen. Mice were immunized with the glycoconjugate to prepare chlamydia-specific monoclonal antibodies. They were selected with chlamydia-specific LPS antigens and the structurally and antigenically related Re-type LPS of a Salmonella minnesota rough mutant. Characterization of the selected antibodies was by (i) hemagglutination of sheep erythrocytes coated with recombinant chlamydia-specific LPS, (ii) inhibition by synthetic polyacrylamide derivatives containing the genus-specific epitope or partial structures thereof, (iii) enzyme immunoassay with recombinant LPS and synthetic bovine serum albumin glycocon,jugates as solid-phase antigens, (iv) immunofluorescence of L929 monolayers infected with Chlamydia psitfaci or C. trachomatis, and (v) Western immunoblots with glycoconjugates and LPS as the antigen. Two groups of monoclonal antibodies were obtained; the monoclonal antibodies in one group cross-reacted with chlamydial and Re-type LPS, but those of the other group were chlamydia specific. Among the latter, KDO trisaccharide-specific antibodies that had the same epitope specificity as antibodies obtained after immunization with chlamydial elementary bodies were identified; however, they exhibited a more than 100-fold higher affinity. In addition, antibodies that bound preferentially to the 2.8-linked KDO disaccharide were detected, although with lower affinity. The data show that the artificial glycoconjugate antigen is similar to its natural counterpart.
Bacteria of the genus Chlamydia are pathogenic, obligatory phagosomal intracellular parasites that cause acute and chronic diseases in animals and humans. Chlamydia psittaci, C. trachomatis, and C. pneumoniae, which are species of the monogeneric family Chlamydiaceae, have a developmental cycle in which infectious, metabolically inactive elementary bodies and noninfectious, multiplying reticulate bodies are produced (21, 29) . The pathogenic potential of these microorganisms is not known. However, recent data on the surface antigens of chlamydiae, in particular on the 39.5-kDa major outer membrane protein and the lipopolysaccharide (LPS), lead one to speculate on their significance as virulence factors. The antigenic activity of the LPS is shared by all chlamydiae, and thus the LPS represents a genus-specific antigen (10) . Elucidation of the molecular structure of chlamydial LPS was hampered by poor growth of the microorganism in quantities large enough to allow purification and structural analysis of isolated LPS. The tools of molecular biology are hardly adaptable to chlamydial genetics, since no controlled system of recombination is available. The cloning and expression of chlamydial genes in Escherichia coli (31) and production of monoclonal antibodies to chlamydial LPS (9) allowed the cloning of a DNA fragment of chlamydial genomic DNA expressing the genusspecific antigen (22) . The molecular basis of this phenomenon was studied by transforming enterobacterial Re mutants (3, 6) with the cloned chlamydial gene(s) and comparing the structures of the recombinant and parent LPSs. Studies such * Corresponding author.
as these showed that the chlamydia-specific LPS contained, in its saccharide portion, a trisaccharide of 3-deoxy-Dmanno-2-octulosonic acid (KDO) of the sequence a-KDO (2-*8)-a-KDO(2--34)-a-KDO (KDO3) (1) . The 2.4-linked disaccharide part of the trisaccharide was from the parent Re LPS, and the 2.8-linked moiety is the structural characteristic of chlamydial LPS. At the same time, the appearance of the 2.8-linked third KDO was paralleled by the concomitant expression of the genus-specific chlamydial epitope (1) . Thus, the KDO region represented the immunodominant segment of chlamydial LPS. The complete carbohydrate backbone of chlamydia-specific recombinant LPS, isolated after deacylation and dephosphorylation, is a pentasaccharide in which the KDO trisaccharide is a-2.6 linked to the C-6' of the P1.6-linked glucosamine disaccharide of lipid A (13) . These analytical data were confirmed by chemical synthesis, which also allowed the synthesis of artificial glycoconjugates (15, 17) . These compounds were serologically characterized by using monoclonal antibodies obtained after immunization with whole elementary bodies. The minimal structure to which these antibodies bound was the KDO trisaccharide (13) . In addition to the chlamydia-specific epitope, other epitopes were identified in the KDO region; i.e., the a-pyranosidically linked terminal KDO and the ao-2.4-linked disaccharide portion (28) . These latter structures in other LPSs (3) explain serological cross-reactions between chlamydiae and various gram-negative bacteria (5, 7-9, 23, 24) . Do these synthetic antigens also represent artificial immunogens when injected into experimental animals? We report 
a Determined by the thiobarbiturate assay (2) .
bPA, polyacrylamide.
ot-KDO(2--4)-cx-KDO(2--36)-GlcNAc (KD03-GlcNAc) covalently linked to a protein carrier. We show below that the antibodies selected have the same specificity but a significantly higher affinity than those prepared against the native chlamydial LPS.
MATERIALS AND METHODS
Bacteria and bacterial LPS. The rough mutant of Salmonella minnesota chemotype Re (strain R595) was transformed (6) with plasmid pFEN207 (22) . LPSs from the resulting recombinant and the parent strain were extracted with phenol-chloroform-petroleum ether (12) and purified by repeated ultracentrifugation. Finally, the LPSs were converted to uniform triethylammonium salts after electrodialysis (11) and are called r595-207 and R595. Partially de-Oacylated and de-O-acylated and dephosphorylated LPSs were prepared as reported elsewhere (27) . The formation of LPS-bovine serum albumin (BSA) complexes was carried out by mixing equal quantities in water (5 mg/ml) and then subjecting the samples to three cycles of lyophilization and solubilization.
Artificial antigens. (i) Chemical synthesis of carbohydrate
as reported previously (15) (16) (17) .
(ii) Synthesis of polyacrylamide derivatives containing carbohydrate ligands with spacers. The above allylglycosides were reacted with cysteamine as reported previously (20) , leading to ligands with spacers of the general formula R-(CH2)3-S-(CH2)2-NH3+, where R represents the respective carbohydrate ligand (Table 1) . These compounds were reacted with acryloyl chloride (26) , resulting in the formation of derivatives of the general formula R-(CH2)3-S-(CH2)2-NH-CO-CH=CH2, which, after copolymerization with acrylamide (14) , yielded polyacrylamide derivatives of the general formula shown in Fig. 1A .
(iii) Synthesis of BSA-glycoconjugates containing spacered carbohydrate ligands with spacers. Ligands with spacers of the general formula R-(CH2)3-S-(CH2)2-NH3' were activated into isothiocyanate derivatives as follows. Thiophosgen (6 ,ul) was dissolved in chloroform (3 ml), and a solution of the ligand with spacers (15 mg) in water (3 ml) was added. The reaction was monitored by using thin-layer chromatog- (iv) Synthesis of amphiphilic partial structures of LPS. Serology. (i) EIA. In the EIA, two types of antigen were used as the solid phase: LPS-BSA complexes and synthetic BSA-glycoconjugates were coated onto PolySorp and MaxiSorp microtiter plates (U-bottom plates; both from Nunc), respectively. The conditions described below were the same for both antigens; however, Tween 20 was omitted when LPS-BSA complexes were used. Unless stated otherwise, SO-,lI volumes were used. Microtiter plates were coated with the respective antigen solution in 50 mM carbonate buffer (pH 9.2) at 4°C overnight. Plates were washed four times with PBS supplemented with 0.05% Tween 20 (Sigma) and 0.01% thimerosal (PBS-T); this buffer was used also in the following washing steps. Plates were blocked with PBS-T supplemented with 15% heat (56°C for 30 min)-inactivated bovine serum (PBS-TBS) for 1 h at 37°C on a rocker platform followed by two washing cycles. Appropriate antibody dilutions in PBS-TBS were added and incubated for 1 h at 37°C.
After a wash, peroxidase-conjugated goat anti-mouse immunoglobulin G (IgG) or M (IgM) (heavy chain specific; Dianova) was added (diluted 1:500 to 1:1,000), and incubation was continued for 1 h at 37°C. After the plates were washed in PBS-T, they were washed twice in substrate buffer (0.1 M sodium citrate, pH 4.5). The substrate solution was freshly prepared as follows: 1 mg of azino-di-3-ethylbenzthiazolinsulfonic acid was dissolved in 1 ml of substrate buffer with sonication in an ultrasound water bath for 3 min, and then hydrogen peroxide (25 p1 of a 0.1% solution) was added. After 30 min at 37°C, the reaction was stopped by the addition of 2% aqueous oxalic acid and the plates were read by using a microplate reader (Dynatech MR 700) at 405 nm. In competitive EIAs, twofold dilutions of unlabeled antibody (100 ,ul) were mixed with equal volumes of a dilution of biotinylated antibody; without the addition of competing antibody, this preparation had anA405 of 1 separated on a 15% polyacrylamide gel and then transferred to nitrocellulose. Monoclonal antibody A20 was used at a concentration of 1.5 ,ug/ml; all others were used at a concentration of 15 pug/ml. The reaction was developed with alkaline phosphatase-conjugated goat anti-mouse IgM and IgG, respectively, and 5-bromo-4-chloro-3-indoylphosphate p-toluidine andp-nitroblue tetrazolium chloride (Bio-Rad) as substrates.
(v) Dot blots. For dot blots, the mycobacteria in Freund complete adjuvant (Difco) were sedimented by centrifugation, washed successively in ether, acetone, and ethanol, lyophilyzed, and suspended in PBS at a concentration of 2 mg/ml. Aliquots (0.1 to 10 p,g) were spotted on nitrocellulose, dried, and stained with monoclonal antibodies as described above for Western blots. Purified elementary bodies of C. trachomatis serotype L2 and C. psittaci 6BC were used in parallel.
RESULTS
Synthesis of glycoconjugates containing carbohydrate partial structures of chlamydial LPS. The tetrasaccharide KD03-GIcNAc, the trisaccharide KDO3, the disaccharides a-KDO (2--8)-ox-KDO and a-KDO(2--4)-a-KDO, and the a-KDO monosaccharide were synthesized and appropriately derivatized to allow covalent binding of high-molecular-weight carriers. The carbohydrate ligands were either copolymerized with acrylamide, yielding linear polyacrylamide derivatives, or coupled with BSA. In both cases, the ligand was incorporated by a spacer to allow free excess of antibodies tested (Fig. 1) polyacrylamide derivatives, the range was 140 nmol/mg for the most bulky and thus the least reactive ligand, KD03-GlcNAc, to 660 nmol/mg for the a-KDO monosaccharide. In BSA conjugates, the range was 38 to 119 nmol/mg (Table 1) . BSA conjugates were examined by using PAGE and staining ( Fig. 2A and B) or by Western blot analysis (Fig. 2C and D) . A monoclonal antibody recognizing a single KDO (27) reacted with all five antigens (Fig. 2C) , whereas the KDO trisaccharide-specific antibody S25-23 (see below) only reacted with KD03-BSA and KD03-GlcNAc-BSA (Fig. 2D,  lanes 4 and 5) .
Selection of monoclonal antibodies after immunization with synthetic KD03-GlcNAc-BSA. Mice were immunized with synthetic KD03-GlcNAc-BSA over 2 months as described in Materials and Methods. Hybridomas were screened for specific antibody production by EIA with R595 and recombinant r595-207 LPS complexed with BSA as well as synthetic KD03-GlcNAc-BSA as a solid-phase antigen. High concentrations of antigen were used to coat the EIA plates to facilitate detection of low-affinity antibodies. Two types of antibody specificity were obtained; antibodies of one type reacted with all antigens, and those of the other type reacted with r595-207 LPS and with KD03-GlcNAc-BSA but not with R595 LPS (Table 2) . Antibodies of the latter type were chlamydia specific, whereas those of the former type recognized cross-reactive epitopes present in the LPSs of S. minnesota R595 and chlamydiae. As SRBCs coated with recombinant r595-207 LPS were used.
See Table 1 and Fig. 1 for chemical structures. c Means of at least two values not differing by more than one dilution step.
GlcNAc-PA but not with KDO mono-or disaccharide antigens, even at 300-fold-higher concentrations. Therefore, these monoclonal antibodies bound the KDO trisaccharide as the minimal structure. S25-2 and S25-27 exhibited a more complicated reaction pattern. Both antibodies were inhibited similarly by 2.8-KDO2-PA, KD03-PA, and KD03-GlcNAc-PA but also by 2.4-KDO2-PA and, in the case of S25-27, by KDO-PA, although 5 to 10 times less effectively. A similar pattern was observed in Western blots with glycoconjugates as antigens (data not shown). However, when LPS was separated by PAGE and transferred to nitrocellulose, S25-2 and S25-27 reacted in a chlamydia-specific way; i.e., they bound to r595-207 LPS but not to R595 LPS (Fig. 3) .
Determination of epitope specificities by EUI. Antibodies were tested in a solid-phase EIA by checkerboard titrations with KDO-BSA, 2.4-KDO2-BSA, 2.8-KDO2-BSA, KD03-BSA, and KD03-GlcNAc-BSA as antigens. The range of antibody concentrations was from 5 to 5,000 ng/ml, and the antigen concentration ranged from 0.2 to 30 pmol of carbohydrate ligand per well. The lowest antibody dilution yielding an optical density of >1.0 with the respective antigen (1.9 pmol of carbohydrate ligand per well) is given in Table 4 . At this low epitope density, the most distinct reactivity pattern was observed with high-affinity antibodies. Monoclonal an- were separated by PAGE (15% polyacrylamide), transferred to nitrocellulose, and reacted with monoclonal antibodies. The crossreactive monoclonal antibodies were A20 (A) and A25 (B), which recognize a single a-pyranosidically linked KDO residue and the oa-2.4-linked KDO disaccharide, respectively (27, 28) . The chlamydia-specific antibodies were the KD03-specific monoclonal antibodies S25-5 (C), S25-23 (D) , and S25-26 (E) and the 2.8-KDO2-reactive monoclonal antibodies S25-2 (F) and S25-27 (G). All antibodies were used at 15 ,g/ml except A20, which was used at 1.5 ,ug/ml. tibodies S25-5, S25-23, and S25-26 reacted with KD03-BSA and KD03-GlcNAc-BSA with differences not exceeding one dilution, and they were not reactive with the KDO disaccharide and monosaccharide antigens. Monoclonal antibodies S5-10 and L21-6, obtained after immunization with elementary bodies of C. psittaci and C. trachomatis, respectively, exhibited a similar reaction pattern but at much higher concentrations. The specificity of this reaction was shown by using higher epitope densities (30 pmol of carbohydrate ligand per well). Under these conditions, clones S5-10 and L2I-6 bound equally to KD03-BSA and KD03-GlcNAc-BSA with 39 and 78 ng/ml, respectively, and to 2.8-KDO2-BSA with 5 pg/ml.
Monoclonal antibodies S25-2 and S25-27 gave similar reactivities with 2.8-KDO2-BSA, KD03-BSA, and KDO3-GlcNAc-BSA as antigens. They also reacted with KDO-BSA and 2.4-KDO2-BSA, although to a significantly lesser extent. To exclude the possibility that these reactivities were caused by different coating efficiencies of the glycoconjugates, the monoclonal antibody A20 (28), which recognized a single a-pyranosidically linked KDO residue, was used as a positive control. Similar reactivities of A20 with all five antigens indicated that the glycoconjugate epitopes were similarly exposed after immobilization on the plates. Also, in Western blots A20 was able to bind to all antigens tested (Fig. 2B) . Therefore, the minimal structure required for binding was the KDO trisaccharide for clones S25-5, S25-23, and S25-26 and the 2.8-linked KDO disaccharide for monoclonal antibodies S25-2 and S25-27.
Comparison of KDO trisaccharide-specific monoclonal antibodies. Antibody binding curves were determined in the EIA by testing dilutions of monoclonal antibodies against 2 pmol of ligand per well (Fig. 4) . The highest affinity was observed with clone S25-23, which still reacted at 2 ng/ml. Monoclonal antibodies S25-5 and S25-26 were eight times less reactive. However, S5-10 and L21-6 were at least 2 orders of magnitude less reactive than clone S25-23. Similar results were obtained when KD03-GlcNAc-BSA instead of KD03-BSA was used as a solid-phase antigen (data not shown).
Monoclonal antibody S25-23 (Fig. 5) . However, the antibody concentrations required for 50% inhibition varied from 300 ng to 5 ,ug/ml, confirming the differences in affinity described above (Fig. 4) .
DISCUSSION
Bacteria of the genus Chlamydia share a common LPS antigen, known as the group-specific antigen, that is active in complement fixation assays to determine antibodies against chlamydiae (10) . Although the LPS is a major surface antigen, its molecular structure remained obscure for many years. The combination of molecular genetics (22, 31) , hybridoma technology (9), and analytical (1, 3, 23) and synthetic (15, 17) found to be the minimal structure allowing binding of chlamydia-specific antibodies (13) .
In the present study we asked two questions: (i) are synthetic glycoconjugates, which are assumed to represent the complete genus-specific epitope, able to induce antibody specificities similar to those observed after immunization with bacteria, and (ii) is the 2. (28) , they were not investigated further in our study. The remaining five monoclonal antibodies were differentiated into those recognizing the 2.8-linked KDO disaccharide (S25-2 and S25-27) or those recognizing the KDO trisaccharide (S25-5, S25-23, and S25-26). The latter antibodies were specific for the KDO trisaccharide. The disaccharide-reactive antibodies had an absolute requirement for the 8-substituted KDO in the hemagglutination test (Table 2 ) and in Western blots with LPS as the antigen (Fig. 3) . However, they reacted in inhibition assays to some extent with the 2.4-linked KDO disaccharide, and S25-27 also reacted with the KDO monosaccharide, when both antigens were presented as polyacrylamide derivatives (Table 3 ). In the EIA and Western blots (data not shown), the reactivity of S25-2 and S25-27 with glycoconjugates was not as strict as that of the trisaccharide-reactive antibodies. Although the antibodies bound preferentially to the 2.8-linked disaccharide, some reactivity was seen with the 2.4-linked disaccharide and KDO monosaccharide. These assay-dependent differences are probably related to the physicochemical presentation. When LPS is integrated into the SRBC membrane via its lipid A anchor, the flexibility of the surface-exposed KDO moiety is probably limited. In the inhibition assay, binding of the atibody to the competing inhibitor is facilitated by the spac: ? arm molecule in the polyacrylamide derivatives. In addi,lon, the affinity of the disaccharide-reactive clones is significantly lower than that of the trisaccharide-reactive clones. Whereas the former bind in the EIA at concentrations ranging from 0.3 to 5 ,ug/ml, the best among the latter (S25-23) even binds at 2 ng/ml. Therefore, clones S25-2 and S25-27 are not able to define chlamydia specificity in all of the assays used. However, the data indicate that chlamydia specificity may also exist on the disaccharide level. Further experiments will show whether disaccharide-reactive and chlamydia-specific antibodies with higher affinity can be prepared.
We have compared the monoclonal antibodies against chlamydial LPS described in this study with those reported earlier. Immunization with the synthetic glycoconjugate antigen KD03-GlcNAc-BSA is able to induce antibodies with the same epitope specificity as those observed after immunization with whole elementary bodies. In addition, a broader spectrum of antibodies was induced with orders of magnitude higher in affinity. Figure 6 shows schematically the binding domains for each of the antibody specificities in the carbohydrate backbone of chlamydial LPS. Also illustrated are the antibody binding sites against KDO structures present in other LPSs that cross-react with chlamydial LPS.
With this study, we have fulfilled for the characterization of bacterial surface antigens what Koch's postulates are for infectious diseases: identification of a bacterial surface structure as an antigen, determination of its chemical and antigenic structure, preparation and characterization of monoclonal antibody binding sites, chemical synthesis of the epitopes, and finally proof that the synthetic product has the same antigenic and immunogenic properties as its natural counterpart.
